logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12161629 B1

PDFFull Text
Date of Patent:
Dec. 10, 2024

Filed:

Oct. 15, 2019

Methods and compositions for treatment of glaucoma and related conditions

Applicant:

Opus Genetics, Inc., Farmington Hills, MI (US);

Inventors:

William H. Pitlick, Seattle, WA (US);

Alan R. Meyer, North Riverside, IL (US);

Mina Sooch, Bloomfield, MI (US);

Konstantinos Charizanis, Ypsilanti, MI (US);

Assignee:

Opus Genetics, Inc., Farmington Hills, MI (US);

Attorney:

Dechert LLP

Primary Examiner:

Jonathan S Lau

Int. Cl.
CPC ...
A61K 31/417 (2006.01); A61K 9/00 (2006.01); A61K 31/138 (2006.01); A61K 31/222 (2006.01); A61K 31/27 (2006.01); A61K 31/382 (2006.01); A61K 31/4045 (2006.01); A61K 31/4164 (2006.01); A61K 31/4168 (2006.01); A61K 31/4178 (2006.01); A61K 31/439 (2006.01); A61K 31/444 (2006.01); A61K 31/4704 (2006.01); A61K 31/472 (2006.01); A61K 31/475 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/5575 (2006.01); A61K 31/558 (2006.01); A61K 31/683 (2006.01); A61K 31/7076 (2006.01); A61K 45/06 (2006.01); A61P 27/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/417 (2013.01); A61K 9/0048 (2013.01); A61K 31/138 (2013.01); A61K 31/222 (2013.01); A61K 31/27 (2013.01); A61K 31/382 (2013.01); A61K 31/4045 (2013.01); A61K 31/4164 (2013.01); A61K 31/4168 (2013.01); A61K 31/4178 (2013.01); A61K 31/439 (2013.01); A61K 31/444 (2013.01); A61K 31/4704 (2013.01); A61K 31/472 (2013.01); A61K 31/475 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/5575 (2013.01); A61K 31/558 (2013.01); A61K 31/683 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); A61P 27/06 (2018.01);
Abstract

Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and/or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.

Find Patent Forward Citations

Loading…